Current price $39.18 crossed the resistance line at $40.81 and is trading between $40.81 resistance and $31.75 resistance lines. Throughout the month of 08/17/21 - 09/17/21, the price experienced a +2% Uptrend, while the week of 09/10/21 - 09/17/21 shows a -0.72% Downtrend.
Signals about CHNA
Under normal circumstances, at least 80% of the fund's total assets (exclusive of any collateral held from securities lending) will be invested in the component securities of the index or in depositary receipts representing such component securities. The index seeks to track the performance of a modified equal-weighted portfolio of companies directly involved in the growth of China's pharmaceutical and biotech related industries. The fund is non-diversified.
The average market capitalization across the Loncar China BioPharma ETF ETF is 6.5B. The market cap for tickers in the group ranges from 631.4M to 35.8B. BGNE holds the highest valuation in this group at 35.8B. The lowest valued company is ADAG at 631.4M.
The average weekly price growth across all stocks in the Loncar China BioPharma ETF ETF was -0.72%. For the same ETF, the average monthly price growth was 1.58%, and the average quarterly price growth was 4.49%. LEGN experienced the highest price growth at 17.22%, while ADAG experienced the biggest fall at -7.25%.
The average weekly volume growth across all stocks in the Loncar China BioPharma ETF ETF was 233.1%. For the same stocks of the ETF, the average monthly volume growth was 158.66% and the average quarterly volume growth was 31.15%
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
| TICKER / |
| CORRELATION |
| 55% |
| 48% |
| 43% |
| 39% |
| 35% |